Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600458 | 0.80 | KDM4E (0.34) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4429156 | 0.79 | KDM4E (0.44) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL837013 | 0.75 | DAO (0.53) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL16892342 | 0.73 | KDM4E (0.48) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12930250 | 0.73 | KDM4E (0.42) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL26912696 | 0.71 | DYRK1A (0.34) | CYP2A6MAOAMAOB | |
| SCHEMBL26912724 | 0.71 | RHEB (0.38) | CYP2A6TDP1 | |
| SCHEMBL26912475 | 0.71 | CYP2A6 (0.43) | ALDH1A1CGASCYP2A6MAPTTDP1 | |
| SCHEMBL21983724 | 0.70 | KDM4E (0.44) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL19014155 | 0.70 | MAPT (0.39) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3377483-B9 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| CN-108349949-B | N-substituted indole derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
| US-7138424-B2 | Indole derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| EP-1507758-B1 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | SANOFI AVENTIS (FR) | 2005-11-02 | — | — | EP | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| EP-1507758-A2 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | Sanofi-Aventis (FR) | 2005-02-23 | — | — | EP | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| WO-2003097597-A2 | INDOLE DERIVATIVES AND THE USE THEREOF AS CB2 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2003-11-27 | — | — | WO | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HTT 3932/4885SMN1; SMN2 4553/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HTT 3932/4885SMN1; SMN2 4553/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HTT 3932/4885SMN1; SMN2 4553/4885 |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | KDM4E 2393/4885HTT 3373/4885SMN1; SMN2 4232/4885 |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | CNR2, CNR1, IDO2 | KDM4E 1563/4885HTT 3585/4885SMN1; SMN2 4762/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 2755/4885HTT 3932/4885SMN1; SMN2 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.